Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Pibrentasvir (formerly ABT-530; ABT530, A-1325912; A1325912; trade name: Mavyret; Maviret), an HCV NS5A protease inhibitor, is an approved antiviral (anti-HCV) drug developed by Abbvie for treating HCV infections. It can be used to treat hepatitis C in the US and EU in combination with glecaprevir as glecaprevir/pibrentasvir (Mavyret).
Targets |
GT5a (EC50 = 1.4 pM); GT1a H77 (EC50 = 1.8 pM); GT2b (EC50 = 1.9 pM); GT4a (EC50 = 1.9 pM); GT3a (EC50 = 2.1 pM)
|
---|---|
ln Vitro |
Pibrentasvir is a potent pan-genotypic next-generation HCV NS5A inhibitor that retains activity against common amino acid substitutions of HCV genotypes 1–6, which are known to confer resistance to NS5A inhibitors that are currently approved.[1]
|
Cell Assay |
Southern Research Institute conducts assays for antiviral activity against HBV and HIV-1. Pibrentasvir is evaluated in an HIV-1 antiviral cytoprotection assay with the IIIB strain of the virus and CEM-SS cells. In short, the virus and cells are combined and incubated for six days in the presence of pibrentasvir or zidovudine (AZT; positive control). The virus titers are predetermined so that the control wells infected with the virus showed between 85% and 95% of the cells' viability being lost as a result of virus replication. Consequently, the observation of an antiviral effect or cytoprotection occurs when a compound hinders the replication of viruses. Twenty to twenty-five microliters of MTS reagent are added to each well six days after infection, and the microtiter plates are then incubated for four to six hours in order to measure the viability of the cells. Plates are read using a Molecular Devices Vmax or SpectraMax Plus plate reader spectrophotometrically at 490/650 nm.
|
References |
Molecular Formula |
C57H65F5N10O8
|
---|---|
Molecular Weight |
1113.2
|
Exact Mass |
1,112.49
|
Elemental Analysis |
C, 61.50; H, 5.89; F, 8.53; N, 12.58; O, 11.50
|
CAS # |
1353900-92-1
|
Related CAS # |
1821461-48-6 (butanamine hydrate);1353900-92-1 (free);
|
Appearance |
Solid powder
|
SMILES |
C[C@H]([C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C(=C3)F)[C@H]4CC[C@@H](N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)NC(=O)OC)OC
|
InChi Key |
VJYSBPDEJWLKKJ-NLIMODCCSA-N
|
InChi Code |
InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1
|
Chemical Name |
methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2S)-1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate
|
Synonyms |
ABT-530; ABT 530; ABT530; A-1325912; A1325912; A 1325912; A 1325912.0; A1325912.0; A-1325912.0; Pibrentasvir
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.8983 mL | 4.4916 mL | 8.9831 mL | |
5 mM | 0.1797 mL | 0.8983 mL | 1.7966 mL | |
10 mM | 0.0898 mL | 0.4492 mL | 0.8983 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05637879 | Not yet recruiting | Drug: Glecaprevir/pibrentasvir Other: Placebo |
PTSD | White River Junction Veterans Affairs Medical Center |
July 1, 2023 | Phase 2 Phase 3 |
NCT04575896 | Active Recruiting |
Drug: Glecaprevir/pibrentasvir | End Stage Renal Disease Hepatitis C |
Johns Hopkins University | November 20, 2020 | Phase 4 |
NCT04903626 | Recruiting | Drug: Glecaprevir/Pibrentasvir (GLE/PIB) |
Hepatitis C Virus (HCV) |
AbbVie | August 24, 2021 | Phase 3 |
NCT05446857 | Recruiting | Drug: Glecaprevir/Pibrentasvir Pill | PTSD | White River Junction Veterans Affairs Medical Center |
April 1, 2023 | Phase 2 Phase 3 |
NCT03855917 | Recruiting | Drug: Sofosbuvir 400mg [Sovaldi] Drug: Glecaprevir/pibrentasvir (300mg/120mg) |
Hepatitis C | Kirby Institute | February 11, 2020 | Phase 4 |